

**FUND UPDATE: September 2024** 

## Fund objective and strategy

Ampersand Growth Opportunities Fund Scheme-1 (AGOFS) seeks to generate long term capital appreciation by investing in a portfolio of listed equity and equity related securities. AGOFS will follow a multi-cap strategy focusing on investment opportunities across the growth themes with a typical portfolio of 30-35 stocks.

| <b>Fund facts</b> |                       |           |                        |             |           |
|-------------------|-----------------------|-----------|------------------------|-------------|-----------|
| Fund Size         | <b>Inception Date</b> | Unit NAV  | <b>Unit Face Value</b> | Benchmark   | Category  |
| INR 793.1cr       | 25 SEP 2017           | INR 504.1 | INR 100                | S&P BSE 500 | Multi-cap |

#### Fund Performance: Mixed showing, lagged benchmark after extended run

Ampersand fund NAV rose 1.5% in September, ahead of other mid and small cap indices. However, our performance lagged both Nifty and benchmark BSE 500 for the first time this financial year, mainly due to significant advance tax outgo during the month. Co-incidentally, the last occasion this had happened was in March 2024, and again for the same reason. Our portfolio had a mixed showing, with several stocks registering reasonable gains, but select few hurting us immensely.

Our performance across various time periods continues to exhibit a consistently superior showing. Since inception in Sept 2017, our fund has delivered around 26% CAGR, well ahead of all major indices.

**Table 1: Fund and Market Performance** 

| Returns          | 1<br>Month | 3<br>Months | 6<br>Months | 1 Year | 3 Year<br>CAGR | 5 Year<br>CAGR | Inception<br>CAGR |
|------------------|------------|-------------|-------------|--------|----------------|----------------|-------------------|
| AGOFS NAV        | 1.5%       | 12.1%       | 36.9%       | 76.5%  | 32.2%          | 34.1%          | 25.9%             |
| BSE 500          | 2.1%       | 7.3%        | 19.3%       | 39.5%  | 16.9%          | 20.9%          | 15.6%             |
| Nifty 50         | 2.3%       | 7.5%        | 15.6%       | 31.4%  | 13.6%          | 17.6%          | 14.5%             |
| Nifty Midcap 100 | 1.5%       | 7.9%        | 25.1%       | 48.4%  | 25.6%          | 30.3%          | 18.4%             |
| AGOFS NAV*       |            |             |             |        |                |                | 504.1             |

<sup>\*</sup> NAV (post expenses & taxes paid till date), Class & Series-wise NAV may differ

**Table 2: Portfolio Metrics** 

| Valuation |      | Risk                 |       |
|-----------|------|----------------------|-------|
| PE        | 44.7 | Standard Deviation * | 18.41 |
| PEG ratio | 1.3x | Beta                 | 0.89  |
| РВ        | 11.4 | Sharpe Ratio         | 1.33  |
| ROCE *    | 23.1 | Capture Ratio        | 1.6x  |

PE, PB & ROCE calculated based on FY25 estimated values. \*ROCE for portfolio is calculated ex-financials.

<sup>\*</sup>Annualised standard deviation of returns has been calculated.

### **FUND UPDATE: September 2024**

#### Core holdings list has undergone couple of alterations

Our Top-5/10 holdings account for ~20% and ~37% of corpus respectively, largely similar to the previous month.

Our core holdings list underwent 2 alterations, with relative stock performances resulting in inclusion of OFSS and Piramal Pharma, at the expense of Phoenix Mills (partial trimming) and REC (severe stock underperformance).

**Table 3: Top Holdings** 

| Company                 | % Weight | Company             | % Weight |
|-------------------------|----------|---------------------|----------|
| Trent                   | 5.3%     | Piramal Pharma      | 3.6%     |
| MCX                     | 4.1%     | OFSS                | 3.5%     |
| TARC                    | 3.9%     | Varun Beverages     | 3.4%     |
| Motilal Oswal Financial | 3.8%     | Divi's Laboratories | 3.4%     |
| Zomato                  | 3.8%     | Polycab India       | 3.4%     |
| Top 5                   | 20.9%    | Top 10              | 37.4%    |

#### Sectoral allocation similar to recent months

Our sector-wise allocation is largely similar to the end of Aug as well as recent months. Consumer remains our preferred investment space, while the Capital goods & Engineering sector has slipped further in ranking due to relative underperformance. Rest of the allocation is also similar to the previous month, including reasonable exposures to the IT, Pharma and Real Estate sectors.

Our weights related to market cap classification witnessed minor alterations, with small caps moving up a tad, due to stock specific movements.

Our cash and equivalents are slightly lower compared to recent months at 5%.

As on Sept 30, 2024, our fund consists of 33 stocks, within our preferred band of 30-35 holdings.

**Table 4: Market Cap Classification** 

**Table 5: Sectoral Allocation** 

| Market Cap                       | % Weight | Sector                   | % Weight |
|----------------------------------|----------|--------------------------|----------|
| < INR 10,000cr                   | 8.0      | Technology               | 16.9     |
| INR 10,000-50,000cr              | 39.1     | Energy Equip & Utilities | 16.0     |
| INR 50,000-100,000cr             | 12.2     | Financial                | 14.3     |
| >INR 100,000cr                   | 35.7     | Consumer Discretionary   | 12.4     |
| Cash & Cash Equivalents          | 5.0      | Healthcare               | 10.0     |
|                                  |          | Real Estate              | 9.8      |
|                                  |          | Materials                | 6.6      |
|                                  |          | Consumer Staples         | 6.2      |
| Weighted Avg. Market Cap (Rs bn) | 1,291.3  | Industrials              | 2.8      |

<sup>\*</sup>Includes Metal and Mining, Hotels & Restaurants



**FUND UPDATE: September 2024** 

#### Gains mostly broad based, sharp underperformance in few names

Key portfolio stocks did well during the month, including MCX, Piramal Pharma and Zomato where our exposure is relatively higher. On the flip side, we faced few sizable reverses in reasonably sized holdings such as REC, Varun Beverages and Ashok Leyland.

**Table 6: Key Movers** 

| Performers     | % Return | % Weight | Laggards        | % Return | % Weight |
|----------------|----------|----------|-----------------|----------|----------|
| Piramal Pharma | 21.2%    | 3.6%     | REC             | -10.5%   | 3.1%     |
| Blue Star      | 21.1%    | 2.7%     | Ashok Leyland   | -8.2%    | 2.8%     |
| TARC           | 9.4%     | 3.9%     | Natco Pharma    | -7.6%    | 2.5%     |
| MCX            | 9.2%     | 4.1%     | Amara Raja      | -6.3%    | 2.8%     |
| Zomato         | 9.1%     | 3.8%     | Sonata Software | -5.2%    | 2.2%     |

Note: Average weight used for stocks bought/sold during the month

#### Results, China-factor and conflict could drive Oct trends

September was expectedly a volatile month for global equities, mainly due to cut in interest rates and increasing possibility of soft landing in the US. With above normal monsoons it seems likely that the RBI too will adopt a shallow rate cut cycle towards the end of CY. However, there are near term issues to contend with namely, (1) quarterly results starting in Oct, (2) flows depending on recent economic stimuli in China, and (3) impact of Israel-Iran conflict on oil prices. We will continue to look forward to any uncertainty and potential dip to buy stocks, as we portend better growth prospects from H2 and end of USA election in Nov 2024.



#### **Fund Information**

Khaitan & Co.

Minimum investmentSubscriptionsRedemptionsRegistered for SaleINR 10 millionMonthlyMonthly, subject toRegistered with SEBI

12 month lock-in

Legal and Fund Consultant Administrator Registrar & Transfer Agent (RTA)

Kotak Mahindra Bank Ltd. CAMS Limited

Statutory Auditor & Tax Consultant Investment Manager

Deloitte Haskins & Sells LLP Ampersand Capital Investment Advisors LLP

## **Investment Manager**

### Ampersand Capital Investment Advisors LLP (LLPIN: AAF -1429)

Address: 75-A, Mittal Tower, Nariman point, Mumbai – 400 021 Tel: +91 22 4213 9500 E-mail: info@ampersand-cap.com

#### DISCLAIMER:

Ampersand Capital Investment Advisors LLP (Ampersand) is an Investment Manager of Ampersand Growth Opportunities Fund Scheme – I (Fund), a Scheme of Ampersand Capital Trust registered as a Category III – Alternative Investment Fund (AIF) under the SEBI (Alternative Investment Funds) Regulations, 2012. This document does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities. The information provided by Ampersand is obtained from sources believed to be reliable but is not guaranteed as to accuracy or completeness and expressly disclaims all warranties and conditions of any kind, whether express or implied.

Ampersand and its employees, personnel, partners will not be responsible for any direct/indirect loss or liability incurred by the user as a consequence of him or any other person on his behalf taking any investment decisions based on the contents and information provided herein. Use of this information is at the user's own risk, as investments in shares and securities are subject to market risks and user's risk profile. The user must make his own investment decisions based on his specific investment objective and financial position and using such independent advisors as he believes necessary. Past performance may not be indicative of future results. All intellectual property rights emerging from this document are and shall remain with Ampersand. This is for your personal use and you shall not resell, copy, or redistribute this document or any part of it, or use it for any commercial purpose.